Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11119 | Pages: NA | Charts: NA | Tables: NA |
Amoxicillin is a type of antibiotic that can be used to treat a number of bacterial infections. These include mainly middle ear infection, strep throat, pneumonia, also skin infections, and other urinary tract infections, among others. Furthermore, it is taken by mouth, or less commonly by injection. Common adverse effects include rash and nausea. It may also boost the risk of yeast infections and when used in combination with clavulanic acid, may cause diarrhea. This should not be used in those who are allergic to penicillin. In addition, it is usable in those with kidney problems, the dose may need to be reduced. The use of Amoxicillin in pregnancy and breastfeeding does not appear to be much harmful.
COVID-19 scenario analysis:
The Pharmaceutical and biotech companies have joined together with governments around the globe in order to manage COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Furthermore there is various development initiatives carried out such that around 115 vaccine candidates and 155 molecules are expected to help in management of coronavirus disease -2. Moreover, the drugs which are successfully showing its effect on the patient such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. The high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. The rise in demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
The major factor affecting the market includes the rise in the incidences of various infectious diseases such as urinary tract infections, chest infection and other bacterial infections would boost the industry in the forecast period. The increase in awareness of the infectious diseases is anticipated to propel the market growth in the coming years. The key advantages offered by amoxicillin is anticipated to help the industry grow in the near future. However, the stringent regulations over the medications would impede the market growth in the near future.
According to the National Kidney Foundation, One in five women will have at least one UTI in her lifetime. Nearly 20 percent of women who have a UTI are anticipated to have another and 30 percent of those will have yet another. Of this last group, 80 percent will have recurrences.
According to the Center for Disease Control and Prevention, the estimated number of deaths due to pneumonia are about 49, 157 and the ration of the population of deaths include, 15.1 in 100,000. The increase in population experiencing infections would propel the market.
In October 2016, Vernalis Therapeutics, Inc. announced that it has begun promoting MOXATAG (amoxicillin extended-release) tablets to primary care physicians in the U.S. MOXATAG is the first and only approved once-daily formulation of the widely-used antibiotic amoxicillin.
Key benefits of the report:
Questions answered in the Amoxicillin Market research report:
Key Market Segments
Key Market Players
Other Players